BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

299 related articles for article (PubMed ID: 23629868)

  • 1. A novel approach to generate a recombinant toxoid vaccine against Clostridium difficile.
    Donald RGK; Flint M; Kalyan N; Johnson E; Witko SE; Kotash C; Zhao P; Megati S; Yurgelonis I; Lee PK; Matsuka YV; Severina E; Deatly A; Sidhu M; Jansen KU; Minton NP; Anderson AS
    Microbiology (Reading); 2013 Jul; 159(Pt 7):1254-1266. PubMed ID: 23629868
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of a recombinant toxin fragment vaccine for Clostridium difficile infection.
    Karczewski J; Zorman J; Wang S; Miezeiewski M; Xie J; Soring K; Petrescu I; Rogers I; Thiriot DS; Cook JC; Chamberlin M; Xoconostle RF; Nahas DD; Joyce JG; Bodmer JL; Heinrichs JH; Secore S
    Vaccine; 2014 May; 32(24):2812-8. PubMed ID: 24662701
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oral Immunization with Nontoxigenic Clostridium difficile Strains Expressing Chimeric Fragments of TcdA and TcdB Elicits Protective Immunity against C. difficile Infection in Both Mice and Hamsters.
    Wang Y; Wang S; Bouillaut L; Li C; Duan Z; Zhang K; Ju X; Tzipori S; Sonenshein AL; Sun X
    Infect Immun; 2018 Nov; 86(11):. PubMed ID: 30150259
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clostridium difficile chimeric toxin receptor binding domain vaccine induced protection against different strains in active and passive challenge models.
    Tian JH; Glenn G; Flyer D; Zhou B; Liu Y; Sullivan E; Wu H; Cummings JF; Elllingsworth L; Smith G
    Vaccine; 2017 Jul; 35(33):4079-4087. PubMed ID: 28669616
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A chimeric protein comprising the glucosyltransferase and cysteine proteinase domains of toxin B and the receptor binding domain of toxin A induces protective immunity against Clostridium difficile infection in mice and hamsters.
    Wang YK; Yan YX; Kim HB; Ju X; Zhao S; Zhang K; Tzipori S; Sun X
    Hum Vaccin Immunother; 2015; 11(9):2215-22. PubMed ID: 26036797
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A DNA vaccine targeting TcdA and TcdB induces protective immunity against Clostridium difficile.
    Zhang BZ; Cai J; Yu B; Hua Y; Lau CC; Kao RY; Sze KH; Yuen KY; Huang JD
    BMC Infect Dis; 2016 Oct; 16(1):596. PubMed ID: 27770789
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A chimeric toxin vaccine protects against primary and recurrent Clostridium difficile infection.
    Wang H; Sun X; Zhang Y; Li S; Chen K; Shi L; Nie W; Kumar R; Tzipori S; Wang J; Savidge T; Feng H
    Infect Immun; 2012 Aug; 80(8):2678-88. PubMed ID: 22615245
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The protective effect of recombinant Lactococcus lactis oral vaccine on a Clostridium difficile-infected animal model.
    Yang XQ; Zhao YG; Chen XQ; Jiang B; Sun DY
    BMC Gastroenterol; 2013 Jul; 13():117. PubMed ID: 23865596
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of an Effective Nontoxigenic Clostridioides difficile-Based Oral Vaccine against C. difficile Infection.
    Wang S; Zhu D; Sun X
    Microbiol Spectr; 2022 Jun; 10(3):e0026322. PubMed ID: 35583336
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Protective efficacy induced by recombinant Clostridium difficile toxin fragments.
    Leuzzi R; Spencer J; Buckley A; Brettoni C; Martinelli M; Tulli L; Marchi S; Luzzi E; Irvine J; Candlish D; Veggi D; Pansegrau W; Fiaschi L; Savino S; Swennen E; Cakici O; Oviedo-Orta E; Giraldi M; Baudner B; D'Urzo N; Maione D; Soriani M; Rappuoli R; Pizza M; Douce GR; Scarselli M
    Infect Immun; 2013 Aug; 81(8):2851-60. PubMed ID: 23716610
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunogenicity of a Salmonella typhimurium aroA aroD vaccine expressing a nontoxic domain of Clostridium difficile toxin A.
    Ward SJ; Douce G; Figueiredo D; Dougan G; Wren BW
    Infect Immun; 1999 May; 67(5):2145-52. PubMed ID: 10225867
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunization with Bacillus spores expressing toxin A peptide repeats protects against infection with Clostridium difficile strains producing toxins A and B.
    Permpoonpattana P; Hong HA; Phetcharaburanin J; Huang JM; Cook J; Fairweather NF; Cutting SM
    Infect Immun; 2011 Jun; 79(6):2295-302. PubMed ID: 21482682
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recombinant Clostridium difficile toxin fragments as carrier protein for PSII surface polysaccharide preserve their neutralizing activity.
    Romano MR; Leuzzi R; Cappelletti E; Tontini M; Nilo A; Proietti D; Berti F; Costantino P; Adamo R; Scarselli M
    Toxins (Basel); 2014 Apr; 6(4):1385-96. PubMed ID: 24759173
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Toll-like receptor 5-dependent immunogenicity and protective efficacy of a recombinant fusion protein vaccine containing the nontoxic domains of Clostridium difficile toxins A and B and Salmonella enterica serovar typhimurium flagellin in a mouse model of Clostridium difficile disease.
    Ghose C; Verhagen JM; Chen X; Yu J; Huang Y; Chenesseau O; Kelly CP; Ho DD
    Infect Immun; 2013 Jun; 81(6):2190-6. PubMed ID: 23545305
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The recombinant Lactococcus lactis oral vaccine induces protection against C. difficile spore challenge in a mouse model.
    Guo S; Yan W; McDonough SP; Lin N; Wu KJ; He H; Xiang H; Yang M; Moreira MA; Chang YF
    Vaccine; 2015 Mar; 33(13):1586-95. PubMed ID: 25698490
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antibody against TcdB, but not TcdA, prevents development of gastrointestinal and systemic Clostridium difficile disease.
    Steele J; Mukherjee J; Parry N; Tzipori S
    J Infect Dis; 2013 Jan; 207(2):323-30. PubMed ID: 23125448
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An optimized, synthetic DNA vaccine encoding the toxin A and toxin B receptor binding domains of Clostridium difficile induces protective antibody responses in vivo.
    Baliban SM; Michael A; Shammassian B; Mudakha S; Khan AS; Cocklin S; Zentner I; Latimer BP; Bouillaut L; Hunter M; Marx P; Sardesai NY; Welles SL; Jacobson JM; Weiner DB; Kutzler MA
    Infect Immun; 2014 Oct; 82(10):4080-91. PubMed ID: 25024365
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A novel fusion protein containing the receptor binding domains of C. difficile toxin A and toxin B elicits protective immunity against lethal toxin and spore challenge in preclinical efficacy models.
    Tian JH; Fuhrmann SR; Kluepfel-Stahl S; Carman RJ; Ellingsworth L; Flyer DC
    Vaccine; 2012 Jun; 30(28):4249-58. PubMed ID: 22537987
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Defining the Roles of TcdA and TcdB in Localized Gastrointestinal Disease, Systemic Organ Damage, and the Host Response during Clostridium difficile Infections.
    Carter GP; Chakravorty A; Pham Nguyen TA; Mileto S; Schreiber F; Li L; Howarth P; Clare S; Cunningham B; Sambol SP; Cheknis A; Figueroa I; Johnson S; Gerding D; Rood JI; Dougan G; Lawley TD; Lyras D
    mBio; 2015 Jun; 6(3):e00551. PubMed ID: 26037121
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Systemic antibody responses induced by a two-component Clostridium difficile toxoid vaccine protect against C. difficile-associated disease in hamsters.
    Anosova NG; Brown AM; Li L; Liu N; Cole LE; Zhang J; Mehta H; Kleanthous H
    J Med Microbiol; 2013 Sep; 62(Pt 9):1394-1404. PubMed ID: 23518659
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.